HM1: A decade of innovative clinical trials: What have we learned and where are we going?
The session gave some insight on the Accelerating Clinical Trials in the EU (ACT EU) and the EMA Q&As on CCTs, a guidance regarding scientific aspects and the planning, set-up and submission for CTA applications, as well as conduct, reporting, analysis and interpretation of CCTs.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.
Not a TOPRA member yet?
Join now to get access to:
- Features and specialist articles
- CPD supplements
- Comprehensive archive
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The Organisation for Professionals in Regulatory Affairs
- Issues
- Contact us
- Topics A-Z
- Contributors A-Z
- © 2023 Regulatory Rapporteur